CCA
REGN icon

Catalyst Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Catalyst Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Sell
23
-17
-43% -$11.6K ﹤0.01% 343
2026
Q1 		$30.9K Hold
40
– – ﹤0.01% 320
2025
Q4 		$30.9K Sell
40
-13
-25% -$8.83K ﹤0.01% 336
2025
Q3 		$29.8K Sell
53
-12
-18% -$6.79K ﹤0.01% 406
2025
Q2 		$34.1K Sell
65
-20
-24% -$11.2K ﹤0.01% 418
2025
Q1 		$53.9K Buy
85
+1
+1% +$688 ﹤0.01% 362
2024
Q4 		$59.8K Hold
84
– – ﹤0.01% 366
2024
Q3 		$88.3K Sell
84
-20
-19% -$22.3K ﹤0.01% 285
2024
Q2 		$109K Buy
104
+3
+3% +$2.91K ﹤0.01% 225
2024
Q1 		$97.2K Buy
101
+1
+1% +$951 ﹤0.01% 218
2023
Q4 		$87.8K Buy
100
+20
+25% +$16.5K ﹤0.01% 207
2023
Q3 		$65.8K Buy
80
+21
+36% +$16.5K ﹤0.01% 241
2023
Q2 		$42.4K Buy
59
+1
+2% +$771 ﹤0.01% 272
2023
Q1 		$47.7K Sell
58
-26
-31% -$19.6K ﹤0.01% 256
2022
Q4 		$60.6K Sell
84
-1
-1% -$738 ﹤0.01% 250
2022
Q3 		$59K Hold
85
– – ﹤0.01% 252
2022
Q2 		$50K Sell
85
-57
-40% -$37.1K ﹤0.01% 278
2022
Q1 		$99K Buy
142
+84
+145% +$53.1K ﹤0.01% 266
2021
Q4 		$37K Sell
58
-31
-35% -$19.1K ﹤0.01% 312
2021
Q3 		$54K Buy
89
+24
+37% +$14.9K ﹤0.01% 304
2021
Q2 		$36K Buy
65
+3
+5% +$1.52K ﹤0.01% 328
2021
Q1 		$29K Sell
62
-12
-16% -$5.84K ﹤0.01% 303
2020
Q4 		$36K Buy
+74
New +$39.9K ﹤0.01% 282
2019
Q2 		– Sell
-100
Closed -$41K – 467
2019
Q1 		$41K Buy
+100
New +$41.2K ﹤0.01% 244
2016
Q2 		– Sell
-10,300
Closed -$3.71M – 523
2016
Q1 		$3.71M Hold
10,300
– – 0.62% 60
2015
Q4 		$5.59M Buy
10,300
+4,500
+78% +$2.44M 0.81% 45
2015
Q3 		$2.7M Sell
5,800
-9,200
-61% -$4.94M 0.36% 86
2015
Q2 		$7.65M Buy
+15,000
New +$7.32M 0.89% 27

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Catalyst Capital Advisors's REGN Position: Q2 2026 in Review

Catalyst Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 43% in Q2 2026, selling an estimated $11.6K and leaving 23 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #343.

Catalyst Capital Advisors first reported a position in REGN in Q2 2015 and has held it in 28 quarters since. The position peaked at $7.65M in Q2 2015. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Catalyst Capital Advisors held 23 shares of Regeneron Pharmaceuticals worth $14.3K as of Q2 2026.
  • Catalyst Capital Advisors sold 17 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $11.6K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #343 holding.
  • Catalyst Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 28 quarters since.
  • Catalyst Capital Advisors's Regeneron Pharmaceuticals position peaked at $7.65M in Q2 2015.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.